Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival (OS). Various salvage chemotherapy strategies have been applied with limited success. Tumor Treating Fields (TTFields) are a novel treatment modality approved for treatment of either newly diagnosed or recurrent GBM. TTFields therapy involves a medical device and transducer arrays to provide targeted delivery of low intensity, intermediate frequency, alternating electric fields to produce antimitotic effects selective for rapidly dividing tumor cells with limited toxicity. In the phase 3 EF-14 trial, TTFields plus temozolomide provided significantly longer progression-free survival and OS compared with temozolomide alone in patients with newly diagnosed GBM after initial chemoradiotherapy. The addition of TTFields to standard therapy improved median OS from 15.6 to 20.5 months (P=0.04). In the phase 3 EF-11 trial, for recurrent GBM, TTFields provided comparable efficacy as investigator’s choice systemic therapy, with improved patient-reported quality of life and a lower incidence of serious adverse events. Primary toxicity associated with TTFields is skin irritation generally managed with array relocation and topical treatments including antibiotics and steroids. TTFields therapy has demonstrated proven efficacy in management of GBM, including improvement in OS for patients with newly diagnosed GBM, and is under current investigation in other brain and extracranial tumors. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Clinical Oncology Wolters Kluwer Health

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma

Download PDF
6 pages

Loading next page...
1
 
/lp/wolters_kluwer/the-evolving-role-of-tumor-treating-fields-in-managing-glioblastoma-EVuGn5YpWn

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
ISSN
0277-3732
eISSN
1537-453X
DOI
10.1097/COC.0000000000000395
Publisher site
See Article on Publisher Site

Abstract

Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival (OS). Various salvage chemotherapy strategies have been applied with limited success. Tumor Treating Fields (TTFields) are a novel treatment modality approved for treatment of either newly diagnosed or recurrent GBM. TTFields therapy involves a medical device and transducer arrays to provide targeted delivery of low intensity, intermediate frequency, alternating electric fields to produce antimitotic effects selective for rapidly dividing tumor cells with limited toxicity. In the phase 3 EF-14 trial, TTFields plus temozolomide provided significantly longer progression-free survival and OS compared with temozolomide alone in patients with newly diagnosed GBM after initial chemoradiotherapy. The addition of TTFields to standard therapy improved median OS from 15.6 to 20.5 months (P=0.04). In the phase 3 EF-11 trial, for recurrent GBM, TTFields provided comparable efficacy as investigator’s choice systemic therapy, with improved patient-reported quality of life and a lower incidence of serious adverse events. Primary toxicity associated with TTFields is skin irritation generally managed with array relocation and topical treatments including antibiotics and steroids. TTFields therapy has demonstrated proven efficacy in management of GBM, including improvement in OS for patients with newly diagnosed GBM, and is under current investigation in other brain and extracranial tumors.

Journal

American Journal of Clinical Oncology – Wolters Kluwer Health

Published: Feb 1, 2018

References

  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
  • Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
  • Cancer statistics, 2014
  • Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial
  • Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
  • A randomized trial of bevacizumab for newly diagnosed glioblastoma
  • Glioblastoma multiforme: overview of current treatment and future perspectives
  • Nonsurgical treatment of recurrent glioblastoma
  • Standards of care for treatment of recurrent glioblastoma—are we there yet?
  • Recent updates in the treatment of glioblastoma: introduction
  • Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
  • Disruption of cancer cell replication by alternating electric fields
  • Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)
  • Tumor treatment fields can enhance the radio- and chemosensitivity of non-small cell lung cancer cell lines
  • Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation
  • The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study
  • NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality
  • Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality
  • Tumor treating fields (TTFields) in recurrent GBM. An updated subgroup analysis of the phase III data (abstract)
  • Subgroup and quality of life analyses of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma
  • NO-50. Comparing the effect of NovoTTF to bevacizumab in recurrent GBM: a post-hoc sub-analysis of the phase III trial data (abstract)
  • Objective response in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure (abstract)
  • Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A system versus best physician's choice chemotherapy
  • Clinical practice experience with NovoTTF-100A system for glioblastoma: the Patient Registry Dataset (PRiDe)
  • Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial
  • LTBK-01: prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma
  • Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma
  • Response patterns of recurrent glioblastomas treated with tumor-treating fields
  • Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
  • Delayed response and survival from NovoTTF-100A in recurrent GBM
  • NovoTTF™-100A system (tumor treating fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study
  • A phase III study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC
  • TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters